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GENETICS
Whole-genome sequencing and early acute 
myocardial infarction
The relative prevalence and importance of monogenic muta-
tions related to familial hyper-cholesterolaemia (FH) and of 
high polygenic score (cumulative impact of many common 
variants) pathways for early-onset myocardial infarction (MI) 
remain uncertain. Whole-genome sequencing enables simulta-
neous ascertainment of both monogenic mutations and poly-
genic score for each individual. Khera, et al.(8) performed whole 
genome sequencing in 2 081 patients hospitalised for early-
onset AMI to assess the prevalence and clinical importance of 
FH mutations and a high polygenic score. They observed an 
FH mutation in 1.7% of patients and a high polygenic score in 
17% of patients – each of which was associated with a greater 
than three-fold increased odds of early-onset AMI. Beyond 
clinical risk stratification, the polygenic score may additionally 
foster insights into the mechanistic underpinnings of AMI. 
Indeed, this risk associated with a high polygenic score is not 
the result of a discrete underlying mechanism, but rather a 
quantitative blend of numerous risk pathways.
PATHOPHYSIOLOGY
Plaque rupture and healing assessed by optical 
coherence tomography
The mechanisms and the pathologic substrate of plaque erosion 
and plaque fissure are different. Indeed, plaques complicated 
by erosion tend to be matrix-rich, lipid-poor, and usually lack 
prominent macrophage collections, unlike plaques that rupture, 
which characteristically have thin fibrous caps, large lipid pools, 
and abundant foam cells.(9) In a prospective study in 211 patients 
with STEMI who underwent pre-intervention optical coher-
ence tomography (OCT) examination for the culprit lesion, 
Tan,  et al.(10)  found that trimethylamine N-oxide (TMAO) 
levels, a gut microbiota-dependent metabolite derived from 
dietary phosphatidylcholine and choline, were significantly and 
independently higher in patients with plaque fissure than in 
those with plaque erosion. The area under the receiver 
operating characteristic curve for distinguishing plaque rupture 
from plaque erosion was 0.89. Thus, plasma TMAO has the 





The management of acute coronary syndromes (ACS) has 
made enormous progress over the last 5 decades due to the 
introduction of defibrillation, beta blockers, thrombolytics, 
aspirin, primary percutaneous transluminal intervention (PCI), 
P2Y12  inhibitors, statins, radial access, and eventually PCSK9 
inhibitors, among others.(1)  However, in spite of all these 
remedies, there is a remaining acute mortality risk, in particular, 
in those presenting in cardiogenic shock or after resuscitation 
and an accruing number of major cardiovascular events (MACE) 
over the following years.(2)  Thus, there is an unmet need in 
the management of ACS. In 2019, there were a number of 
important papers published in the European Heart Journal and 
other journals that deepened our knowledge of the spectrum 
of ACS and their management. Today, patients presenting 
with acute chest pain and changes in the electrocardiogram 
(ECG) or biomarkers may have ST-segment elevation myo-
cardial infarction (STEMI) or non-STEMI (NSTEMI) caused 
by atheroma, coronary dissection,(3)  takotsubo syndrome,(4,5) 
MINOCA (Myocardial infarction with Non Obstructed Coro-
nary Arteries),(6) or myocarditis.(7)
* Department of Cardiology, John Radcliffe Hospital and University 
of Oxford, Oxford, United Kingdom 
# Fondazione Policlinico Univeristario A. Gemelli, Università Cattolica 
del Sacro Cuore, Rome, Italy
† Royal Brompton & Harefi eld Hospital, Imperial College, London, 
United Kingdom 
Address for correspondence: 
Prof Adrian P. Banning
Department of Cardiology
























patients with STEMI, and, indeed, is a prognostic marker in 
these patients (see below). This might be relevant because risk 
stratification and management are probably different for plaque 
fissure and erosion.
Healed plaque ruptures or erosions may be considered as a 
signature of an aborted ACS. However, the role of plaque 
healing in the natural history of ischaemic heart disease (IHD) 
is largely unknown. OCT has been validated for the detection 
of healed coronary plaques against histology and, therefore, 
offers the opportunity of assessing their clinical relevance. 
Vergallo,  et al.(11)  assessed plaque healing in 2 groups of 
patients at the extremes of the clinical presentations of IHD: 
(i) patients with recurring ACS, defined as history of at least 
3 AMIs or at least 4 ACS with at least 1 AMI; and (ii) patients 
with long-standing chronic coronary syndromes, defined as a 
minimum 3-year history of stable angina in the absence of pre-
vious ACS. In the first group, non-culprit plaques only were 
assessed. They found that patients with recurrent ACS had a 
distinct atherosclerotic phenotype compared with those with 
chronic coronary syndrome and longstanding angina, including 
a much lower prevalence of healed coronary plaques, suggesting 
that plaque healing may play a role in leading the natural history 
of patients with IHD.
In another OCT study, Fracassi, et al.(12) assessed plaque healing 
in the culprit stenosis, among 376 patients with ACS and 
found plaque healing in more than one quarter. Such patients 
more frequently were diabetic or hyperlipidaemic; further-
more, healed plaques frequently showed OCT features of local 
and systemic inflammation. This suggests that the combination 
of risk factors and local in addition to systemic inflammation 
may outweigh the protective mechanism of plaque healing and 
predispose those plaques to develop occlusive thrombus. Thus, 
a better knowledge of the mechanisms promoting plaque 
healing might provide new therapeutic targets to reduce ACS 
burden – in addition to optimal risk factor control.
Mechanisms of coronary microvascular obstruction
The rapid re-opening and stenting of occluded epicardial 
coronary arteries via emergency PCI have revolutionised 
STEMI treatment. Despite technical refinements and the intro-
duction of numerous antiplatelet and anticoagulant drugs, more 
than one-third of patients demonstrate coronary microvas-
cular obstruction (CMVO), which deny the benefit of an 
apparently successful PCI. The mechanisms of CMVO are still 
largely unknown, while its prevention and treatment remain an 
unmet need.
Herring,  et al.(13)  found that STEMI patients with the highest 
neuropeptide Y levels in the coronary sinus had significantly 
lower coronary flow reserve, and higher index of microvascular 
resistance measured with a coronary flow wire, both markers 
of CMVO. After 2 days, they also had significantly higher levels 
of myocardial oedema and microvascular obstruction (MVO) 
on magnetic resonance imaging (MRI), and significantly lower 
ejection fractions and ventricular dilatation 6 months later. 
Interestingly, neuropeptide Y (NPY) (100 - 250nM) caused 
significant vasoconstriction of rat microvascular coronary 
arteries via increasing vascular smooth muscle calcium waves, 
and increased coronary vascular resistance and infarct size in 
Langendorff hearts. These effects were blocked by the Y1 
receptor antagonist BIBO3304. Immunohistochemistry of the 
human coronary microvasculature confirmed the presence of 
vascular smooth muscle Y1 receptors. Thus, antagonism NPY 
might be an attractive future therapeutic target in the prevention 
of CMVO (Figure 1).
New insight into post-myocardial infarction remodelling
The immune response to AMI involves two equally important, 
consecutive phases: the inflammatory phase and the reparatory 
phase. During the inflammatory phase, neutrophils and inflam-
matory Ly6Chi  monocytes are recruited into the ischaemic 
myocardium. Subsequently, the Ly6Chi monocytes give rise to 
reparatory Ly6Clo macrophages, with an important role in 
cardiac recovery. A balance between the 2 phases is crucial for 
recovery of cardiac function and patient prognosis. An exces-
sive inflammatory response to AMI amplifies myocardial injury, 
leading to larger infarcts and loss of function. However, clinical 
trials testing anti-inflammatory strategies in AMI have so far led 
to non-significant or even deleterious effects. Ideally, an efficient 
therapy should inhibit the damaging effects of excessive inflam-
mation, while leaving the repair mechanisms intact.
Alarmins are a group of heterogeneous molecules released 
from dying cells and activated leucocytes that signal tissue 
damage and trigger an innate immune response. S100A9 and 
its dimerisation partner S100A8, also called myeloid-related 
proteins 8 and 14, are proinflammatory alarmins that are 
readily produced and stored in large amounts in neutrophils 
and are increased at the site of acute coronary occlusion.(14) 
Marinković, et al.(15) studied 524 patients with ACS and found 
that high plasma S100A8/A9 at the time of ACS was associ-
ated with lower left ventricular ejection fraction (LVEF) at 
1 year and increased hospitalisation for heart failure during 
follow-up. Moreover, in wild-type C57BL/6 mice with AMI 
induced by permanent coronary artery ligation, treatment with 
the S100A9 blocker ABR-238901 during the inflammatory 
phase of the immune response inhibited haematopoietic stem 
cell proliferation and myeloid cell egression from the bone 
marrow. The treatment reduced the numbers of neutrophils 
and monocytes/macrophages in the myocardium, promoted 
an anti-inflammatory environment, and significantly improved 
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cardiac function compared with controls. To mimic the clinical 
scenario, they further confirmed the effects of the treatment 
in a mouse model of ischaemia and reperfusion. Compared 
with untreated mice, 3-day ABR-238901 treatment significantly 
improved LVEF. Thus, S100A9 blockade might represent a 
feasible strategy to improve prognosis in ACS patients.
Tang,  et al.(16)  investigated the effects of gut microbiota on 
cardiac repair after AMI. C57BL/6J mice were treated with anti-
biotics 7 days before AMI to deplete mouse gut microbiota. 
Antibiotic-treated mice displayed drastic, dose-dependent 
mortality after AMI, associated with a reorganisation of the gut 
microbial community such as a reduction in Lactobacillus. The 
physiological status and survival of mice were signif icantly 
improved after faecal reconstitution or dietary supplementa-
tion with short-chain fatty acids that are altered after antibiotic 
treatment; these benefits appeared to be mediated by immu-
nomodulatory effects. In addition, supplementing antibiotic-
treated mice with a Lactobacillus probiotic before AMI restored 
yielded cardioprotective effects. Thus, this study uncovers the 
adverse effects of antibiotics on survival after MI and addresses 
a promising therapeutic strategy that involves modulation of 
gut microbiota composition through probiotic supplementa-
tion (Figure 2).
ACUTE CORONARY SYNDROMES
FIGURE 1: Neuropeptide-Y following primary percutaneous coronary intervention for ST-elevation myocardial infarction 
causes vasoconstriction of the coronary microvasculature and is associated with a high index of microcirculatory resistance and low 
coronary flow reserve, leading to microvascular obstruction, oedema, and eventually a lower ejection fraction and ventricular dilatation. 
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Mechanisms of takotsubo syndrome
In 55 patients with takotsubo syndrome, Scally, et al.(17) found 
myocardial macrophage inflammatory infiltrates as assessed by 
MRI as well as changes in the distribution of monocyte subsets 
and an increase in systemic pro-inflammatory cytokines. Many 
of these changes persisted for at least 5 months, suggesting 
a low-grade chronic inflammatory state. Obviously, whether 
inflammation is a cause or a consequence of the acute takot-
subo event remains to be shown. Moreover, whether inflam-
mation is maladaptive and implicated in the persistence in the 
FIGURE 2: A schaematic diagram showing the importance of gut microbiota-derived short-chain fatty acids for maintaining 
immune composition and repair capacity during homoeostasis.
(A) In untreated mice, gut microbiota-derived short-chain fatty acids modulate immune composition and repair capacity during homoeostasis. 
(B) On antibiotics-mediated dysbiosis, the depletion of the gut microbiota and the short-chain fatty acid products are associated with changes in 
immune composition and an abolishment of repair response, leading to exacerbated mortality after myocardial infarction. Restoration of the 
system across each level through the faecal reconstitution of the gut microbiota, dietary supplementation of short-chain fatty acids, or immune 




































long-term consequences of this condition is uncertain. Never-
theless, inflammation might play a role in the complex patho-
genesis of this syndrome.
Most importantly, novel investigations using functional MRI of 
the brain suggest that an altered limbic and central autonomic 
signal processing plays a crucial role in takotsubo and may 
explain the inappropriately excessive reaction of the sympa-
thetic nervous system to stressful triggers. Thus, takotsubo 




Boeddinghaus,  et al.(19)  prospectively enrolled patients pre-
senting with symptoms suggestive of AMI in 3 large diagnostic 
studies in order to assess the validity of the 0/h-algorithms 
according to age (<55 years, ≥55 - <70 years, and ≥70 years). 
Rule-out safety of the ESC high-sensitivity cardiac troponin T 
(hs-cTnT) 0/1 h-algorithm was very high with a sensitivity of 
>99.3% in all age strata, while triage efficacy decreased with 
increasing age with sensitivity dropping from 93% - 55%. Slightly 
higher cut-off concentrations optimised for older patients main-
tained very high safety of rule-out and increased specificity. 
Findings were confirmed in 2 validation cohorts and also for 
hsTnI. While safety of the ESC 0/1 h-algorithms remained very 
high, increasing age significantly reduced overall efficacy and the 
accuracy of rule-in. Thus, alternative slightly higher cut-off con-
centrations may be considered for older patients, although the 
problem remains for other confounders like chronic kidney 
disease, chronic heart failure, atrial fibrillation, and others that 
also need to be incorporated. Twerenbold, et al.(20) confirmed 
the excellent applicability, short time to emergency depart-
ment discharge, and low rate of 30-day MACE associated with 
the routine clinical use of the ESC 0/1-h-algorithm for the 
management of patients presenting with acute chest discomfort 
to the emergency department in a real-world setting.
Finally, important concepts for institutional transition to hs-cTn 
methodology providing recommendations useful for education 
before implementation have been reported in an Expert Panel 
published by Januzzi, et al.(21)
Implantable cardiac alert system
Symptoms remain a poor prompt for ACS. In a multicentre, 
randomised trial of an implantable cardiac monitor that 
included 907 high-risk ACS patients with rapidly progressive 
ST-segment deviation randomised to a control (alarms 
deactivated) or treatment group for 6 months, after which 
alarms were activated in all subjects,(22) safety revealed a 
96.7% freedom from system-related complications. The pri-
mary efficacy endpoint of cardiac or unexplained death, new 
Q-wave MI, and detection  to presentation time >2 hours 
following a confirmed  occlusive event within 7 days was 
numerically, but not statistically,  reduced among patients 
with activated alarms. When the observation window was 
extended to 50, 70, and 90 days in a pre-specified analysis to 
include the majority of confirmed occlusive events in the 
control group, and an exploratory dual-baseline ECG analysis 
was used to reduce noise, a significant reduction in the pri-
mary endpoint was observed. Moreover, alarms significantly 
decreased detection to arrival time at a medical facility. This 




Among 4 257 patients of the VISTA-16 trial, initial and sub-
sequent increases in high-sensitivity C-reactive protein (hsCRP) 
levels during 16 weeks after ACS were associated with a 
greater risk of the combined MACE endpoint, cardiovascular 
(CV) death, and all-cause death – despite established back-
ground therapies.(23) Further studies will be required to deter-
mine whether initial and serial hsCRP measurements can help 
guide the use of targeted anti-inflammatory therapies after 
ACS or whether more specific inflammatory markers will be 
needed to this end.
Four new biomarkers have been investigated in different trials 
in the setting of ACS: (i) galectin-3, implicated in fibrosis;(24) 
(ii) impaired endogenous fibrinolysis;(25) (iii) trimethyllysine and 
TMAO, gut-microbiota derived metabolite;(26) and (iv) serum 
cholesterol efflux capacity.(27) All these biomarkers were found 
to be independently associated with MACE at follow-up. 
Again, further studies will be required to establish whether 
these markers identify patient subsets who need personalised 
forms of treatment.
Finally, Lindholm,  et al.(28)  assessed the association between 
cystatin-C, growth differentiation factor-15 (GDF-15), hsCRP, 
hs-TnT and TnI, and N-terminal pro-B-type natriuretic pep-
tide (NT-proBNP) and specif ic causes of mortality among 
17 095 ACS patients of the PLATO trial. They found that NT-
proBNP and GDF-15 were strong markers associated with 
all-cause death based on their associations with death due to 
heart failure as well as due to arrhythmia and sudden cardiac 
death. Growth differentiation factor-15 had the strongest 
associations with death due to other vascular or non-vascular 
causes and possibly with death due to bleeding. It remains to 


















Cardiac magnetic resonance and entropy
Entropy is a new late gadolinium-enhanced MRI-derived para-
meter to evaluate tissue inhomogeneity, independent of signal 
intensity thresholds. Androulakis, et al.(29) enrolled 154 consec-
utive post-AMI patients undergoing late gadolinium-enhanced 
MRI prior to implantable cardioverter-defibrillator (ICD) 
implantation. When entropy involved the entire left ventricle 
(LV), this was associated with mortality. After adjusting for 
multivessel disease, acute revascularisation, and ejection frac-
tion, entropy of the scar was independently associated with 
the presence of ventricular arrhythmias. The association 
between LV entropy and mortality may reflect adverse and 
irreversible, inhomogeneous remodelling of the post-infarct 
LV and/or possibly fatal arrhythmias. Further studies are 
warranted to establish whether this new marker can allow a 
better identification of candidates for ICD after AMI.
TREATMENT
Ticagrelor compared to prasugrel were studied in the ISAR-
REACT 5 study (Figure 3).(30) Patients with ACS and a pro-
posed interventional strategy were randomised and the pri-
mary composite endpoint was death, MI, or stroke. In these 
patients with or without STEMI, prasugrel therapy was 
superior to ticagrelor with no difference in bleeding. These 
important comparative data are likely to change clinical practice.
Timing of treatment
The optimal timing of administration of dual antiplatelet ther-
apy (DAPT) in STEMI patients was investigated by the Swedish 
Coronary Angiography and Angioplasty Registry.(31)  Patients 
were stratified between either post- or pre-procedure treat-
ment with P2Y12 receptor antagonists. Of the 44 804 patients, 
58% had been on clopidogrel, 35% on ticagrelor, and 5% on 
prasugrel. There was no survival benefit from pre-treatment or 
any impact on infarct-related artery patency, stent thrombosis, 
or bleeding. These data are surprising as a potential impact on 
early stent thrombosis, in particular, might have been antici-
pated. Existing Guidelines(32)  recommend catheter-lab admini-
stration of antiplatelet drugs and these data are supportive of 
that strategy, although Abtan and Steg(33) argue that we should 
continue to give P2Y12  receptor antagonists as early as pos-
sible in probable STEMI patients, as there is a strong biological 
plausibility of likely benefit with no obvious likely detriment.
Whether patients with transient ST-elevation (patients who 
present initially with ST-elevation on the electrocardiogram 
but, subsequently, show complete normalisation of the ST-
segment and relief of symptoms before reperfusion therapy) 
require immediate revascularisation was studied in a trial(34) 
of 142 patients who were randomised to immediate (mean 
0.3  hours) or delayed angiography (mean 22.7  hours). The 
outcome was infarct size by MRI at Day 4. The observed 
infarcts were generally small and there was no clear benefit 
from the immediate strategy, although 4/71 patients required 
urgent intervention because of further symptoms and ST 
elevation while waiting. Consequently, these data can probably 
be interpreted as allowing decisions about timing of revas-
cularisation in patients with transient STEMI, to be guided by 
the availability of angiography and careful clinical assessment.
The management of non-culprit lesions in STEMI patients has 
been extensively discussed over the last years. Small ran-
domised trials have suggested a probable benefit from com-
plete revascularisation. The large COMPLETE trial randomised 
4 041 STEMI patients (Figure  4) to complete or partial 
revascularisation.(35)  Complete revascularisation was superior 
to culprit-only as it reduced the risk of CV death or AMI. 
There was also benefit from complete revascularisation in 
reducing ischaemic endpoints. Timing appeared to be less 
important and deferring any secondary revascularisation pro-
cedure was safe. Thus, the advantage of complete revas-
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Ticagrelor
Prasugrel
Hazard ratio, 1.36 (95% CI, 1.09 - 1.70)
p=0.006
FIGURE 3: The Kaplan–Meier curves of the ISAR–
REACT(5) show the cumulative incidence of the primary 
endpoint, which was a composite of death, myocardial 
infarction, or stroke at 1 year. 
The inset shows the same data on an enlarged y axis. Reproduced 
with permission from ref.(30)
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Can we tailor treatment in acute coronary syndromes?
There remains a desire to tailor drug therapy to the individual 
patients and perhaps the individual lesion. This strategy would 
allow pharmaceutical optimisation of protection with mini-
misation of side effects or bleeding risk. The CHAMPION 
PHOENIX trial(36)  has suggested that complex coronary 
lesions can be characterised and that it is inadequate treat-
ment of these “high risk” lesions that leads to repeat revas-
cularisation or clinical events. Compared with a loading dose 
of clopidogrel, cangrelor reduced MACE occurring within 48 
hours after PCI in patients with ACS, regardless of baseline 
lesion complexity. However, the absolute benefit: risk profile 
for cangrelor was greatest during PCI in complex coronary 
anatomy. In a substudy of the PROSPECT trial,(37)  virtual his-
tology and grey scale intravascular ultrasound (IVUS) was a 
predictor of a suboptimal final angiographic result reflected as 
a high residual Syntax Score after intervention. A detailed 
Expert consensus review has provided detail on characterisa-
tion of acute coronary lesions using IVUS or OCT and suggested 
a triaged therapeutic approach.(38)
Unfortunately measuring individuals’ responses to antiplatelet 
drugs has not shown clinical utility. Randomising patients to 
measuring platelet function in the TROPICAL trial(39)  showed 
no measurable clinical advantage. Within the trial, those 
patients with maximal platelet inhibition were predictably most 
prone to bleeding.
Optimising treatment in ST-segment elevation 
myocardial infarction
About one-third of STEMI patients have suboptimal reperfu-
sion after PCI and it is this group of patients that might 
experience heart failure and premature death. MRI can pro-
vide evidence of MVO and myocardial haemorrhage.(40) In the 
DANAMI-3 trial, delayed presentation(41) as evidenced by pro-
longed door-to-wire-time predicted adverse clinical outcome, 
consistent with previous observations using intracoronary 
physiology measurements suggesting increased risk in these 
“late presenters”.(42) Enhanced and continued public information 
campaigns are required to optimise outcomes in high-risk 
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Hazard ratio, 0.74 (95% CI, 0.60 - 0.91)
p=0.004
Hazard ratio, 0.51 (95% CI, 0.43 - 0.61)
p<0.001
FIGURE 4: The Kaplan–Meier curves show the cumulative incidence of the primary endpoint, which was a composite of 
death, myocardial infarction, or stroke at 1 year.

















context, full dose intracoronary tenectaplase was inferior to 
abciximab in a small randomised trial(43)  and using low dose 
intracoronary tenecteplase after reperfusion in the T-time trial 
also failed to reduce MVO measured using cardiac magnetic 
resonance imaging (CMRI).(44)
Hypothesis generating results were presented by the  Micro-
vascular Reperfusion Utilising Sonothrombolysis in Acute Myo-
cardial Infarction (MRUSMI) investigators.(45) They randomised 
STEMI patients to either standard PCI or diagnostic ultra-
sound transducer guided, high mechanical index impulses 
during an ultrasound agent transfusion prior to and following 
PCI. The ultrasound’s high mechanical index impulses create 
microbubble cavitation that induce shear forces, designed to 
dissolve intracoronary thrombi. The treatment cohort demon-
strated higher recanalisation (48% vs. 20%) and TIMI 3 flow 
rates (32% vs. 14%) within the infarcted vessel and  ST-seg-
ment resolution prior to primary PCI occurred more fre-
quently. Furthermore, infarct size as assessed by MRI and TNT 
peak values was also reduced by the intervention. Optimising 
reperfusion for patients with STEMI when there is lot of 
thrombus is challenging and these preliminary results hint at a 
possible alternate approach.
Remote preconditioning in STEMI was studied in the CONDI-2/
ERIC PPCI trial,(46) which randomised 5 401 patients to standard 
treatment (including a sham simulated remote ischaemic 
conditioning at UK sites) or remote ischaemic conditioning 
(intermittent ischaemia and reperfusion applied to the arm 
through 4 cycles of 5 minutes inflation and 5 minutes deflation 
of an automated cuff device) before primary PCI. Unfortu-
nately, remote ischaemic conditioning did not improve clinical 
outcomes (cardiac death or hospitalisation for heart failure) at 
12 months. New approaches and therapies within this area are 
warranted if this experimentally well-documented concept 
should ever reach the clinical applicability.
OUTCOMES
Quality of treatment and outcomes
In a cohort of 389 507 NSTEMI patients, optimal care, defined 
as the receipt of all eligible treatments, was inversely related to 
risk status (defined by the GRACE risk score), i.e. 25.6% in low, 
18.6% in intermediate, and 11.5% in high-risk patients. At the 
end of 2.3 years of follow-up, the association between the use 
of all eligible guideline-indicated treatments and improved 
survival remained only significant for high-risk NSTEMI.(47) Thus, 
optimal use of guideline-indicated care for NSTEMI was asso-
ciated with greater survival gains with increasing GRACE risk, 
but its use paradoxically decreased with increasing GRACE 
risk – thus leaving room for improvement.
In the SWEDHEART registry, outcomes of patients presenting 
with NSTEMI followed over 20 years demonstrated a sub-
stantial improvement in long-term survival and reduction in 
the risk of MACE.(48)  These improvements were associated 
with the gradual uptake and widespread use of PCI and long-
term use of evidence-based medications, consistent with the 
anticipated effectiveness of their implementation as proposed 
in guidelines (Figure 5).
The value of a cardiac rehabilitation programme was compared 
in 839 patients who attended a planned programme at dis-
charge after ACS or surgical revascularisation, while 441 
patients were discharged without it.(49)  At multivariable Cox 
proportional hazard analysis, the cardiac rehabilitation pro-
gramme was an independent predictor of lower occurrence 
of MACE (hazard ratio 0.55), while in a propensity-matched 
analysis patients attending the cardiac rehabilitation pro-
gramme also experienced a lower total mortality (10% vs. 19%) 
and CV mortality (2% vs. 7%) compared to non-rehabilitated 
ones. Thus, the positive effects of ambulatory cardiac rehabili-
tation are also notable in a real-world population.
Finally, in a cohort study of 123 780 consecutive PCIs from the 
Pan-London PCI Registry, the outcomes pre- and post-public 
reporting in the UK were compared.(50) After public reporting 
was introduced, patients were older and had more complex 
medical problems, while in-hospital MACE and MACCE and 
30-day mortality rates were significantly lower. These results 
probably reflect continued improvements in PCI outcomes 
concomitant with the introduction of public reporting, but the 
lower reported complication rate could also reflect a change 
in the documentation of risk factors and a change in operator 
behaviour. Reassuring, additional data from the UK registry also 
confirm continued temporal improvement in outcomes in ACS 
and notably demonstrate no difference in outcome depending 
on the times of day that treatment occurred. Patients treated as 
emergencies at night had similar outcomes to those treated 
within “office hours”.
Modes of death after non-ST-segment elevation 
myocardial infarction
In 66  252 patients with NSTEMI enrolled in 14 TIMI trials, 
baseline characteristics and modes and timing of death were 
examined. Of the 2 606 patients with known modes of death, 
75.1% were related to MACE, 3.0% were related to a bleeding 
event (including intracranial haemorrhage), and 21.8% were 
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related to a non-CV/non-bleeding event.(51) The most com-
mon modes of CV death were sudden death and recurrent 
AMI (36.4% and 23.4%, respectively). The proportion of CV 
deaths related to recurrent AMI was higher in the first 30 
days than it was after 30 days following NSTEMI (30.6% vs. 
18.7%), whereas the proportion of sudden death was lower 
in the first 30 days than after 30 days (21.6% vs. 46.2%). Thus, 
sudden death represented the largest proportion of CV 
deaths after 30 days. Further investigations aimed at defining 
management approaches to reduce sudden death following 
NSTEMI may be critical to reducing late mortality.
Outcomes of in-hospital acute coronary syndromes
In a cohort study of 1.3 million patients hospitalised in US 
Veterans Health Administration facilities, an incidence of in-
hospital AMI of 4.27 per 1 000 admissions and risk factors 
associated with in-hospital AMI such as history of IHD, ele-
vated heart rate, low haemoglobin level, and elevated white 
blood cell count were reported.(52)  Compared with matched 
controls, mortality was significantly higher for in-hospital AMI. 
Thus, in-hospital AMI is common and associated with com-
mon CV risk factors and markers of acute illness and with 
high mortality approaching 60% at 1 year. Further studies of 
in-hospital AMI may yield opportunities to reduce in-hospital 
AMI risk and improve patient outcomes.
Outcomes of atypical acute coronary syndromes
Spontaneous coronary artery dissection
Spontaneous coronary artery dissection (SCAD) is an under-
diagnosed and poorly understood condition and an important 
cause of AMI in young women.(3)  In the Canadian multi-
centre, prospective, observational study of 750 patients, pre-
disposing conditions included fibromuscular dysplasia in 31.1%, 
systemic inflammatory diseases in 4.7%, peripartum in 4.5%, 
and connective tissue disorders in 3.6% were noted.(53) Most 
were treated conservatively, while 14% underwent PCI and a 
few coronary artery bypass surgery. In-hospital composite 
MACE was 8.8%, but higher in peripartum SCAD (20.6% vs. 
8.2%). Overall 30-day MACE was 8.8% with peripartum SCAD 
and connective tissue disease being independent predictors of 
30-day MACE.
FIGURE 5: (A and B) Kaplan–Meier estimates of the cumulative incidence of the first coprimary outcome (death from 
cardiovascular causes or new myocardial infarction) and the second coprimary outcome (death from cardiovascular 
causes, new myocardial infarction, or ischaemia-driven revascularisation), respectively.
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Implementation of in-hospital interventions and 
discharge medications
Frequency of events in the first year after 
admission for NSTEMI
NSTEMI in SWEDEHEART 1995 - 2014
A B
Aspirin            Betablocker            ACE-inhibition/ARB
Statin              PCI                        Coronary angiography
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Two different studies of the  InterTak Registry  including over 
1 500 patients with takotsubo syndrome found that both in-
hospital cardiac arrest (4.9% of patients)(54) or the presence of 
an associated malignancy (16.6% of patients)(55)  were asso-
ciated with worse long-term outcome. Of note, patients with 
cardiac arrest were more likely to be younger, male, and have 
apical takotsubo, atrial fibrillation, neurologic comorbidities, 
physical triggers, longer corrected QT-interval, and lower LVEF, 
while those with malignancy were older and more likely to 
have physical triggers, but less likely to have emotional triggers.
Myocardial infarction with non-obstructed 
coronary arteries
The long-term outcome of MINOCA was investigated in a 
large US Registry of 286 780 AMI admissions, of which 5.9% 
had MINOCA.(56) Following risk-adjustment, MINOCA patients 
had a 43% lower risk of MACE over 12 months compared to 
those with AMI and coronary artery disease. This pattern was 
similar for adjusted risks of the MACE components. Thus, 
MINOCA has an unfavourable prognosis in elderly patients – 
with 1 in 5 suffering a major adverse event over 12 months.
FIGURE 6: The spectrum of acute coronary syndromes encompasses plaque rupture and erosion (= Type 1 myocardial 
infarction), Type 2 myocardial infarction, epicardial and microvascular coronary spasm, coronary embolism, acute 
myocarditis, takotsubo syndrome and coronary dissection.
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The impact of gender was assessed in 13  451 NSTEMI and 
STEMI patients undergoing PCI in the  Victorian Cardiac 
Outcomes Registry  in Australia.(57)  Women with STEMI had 
significant delays in presentation and revascularisation with a 
higher 30-day mortality compared with men, while women 
with NSTEMI had no delay in presentation or revascularisation, 
with mortality comparable to men. Thus, public awareness 
campaigns might be needed to address women’s recognition 
and early action for STEMI.
In a Swiss population of 4 360 patients with STEMI, ischaemic 
time in women remained greater than that in men due to 
persistently greater patient delays.(58) In contrast to men, clinical 
signs of ongoing chest discomfort did not predict delays in 
women, suggesting that female STEMI patients were less likely 
to attribute symptoms to a condition requiring urgent treatment.
In a Chinese population of 82 196 patients, women hospitalised 
for ACS less frequently received acute treatments and strategies 
for secondary prevention than men.(59)  The observed sex 
differences in in-hospital mortality were mainly due to worse 
clinical profiles and fewer evidence-based acute treatments 
provided to women with ACS.
Finally, Vicent, et al.(60) in an octogenarian Spanish population of 
535 patients with STEMI found that female sex was 
independently associated with death and hospitalisation at 
6-month follow-up.
Medicaid benefi ciaries vs. privately insured individuals
In 42 645 and 171 545 STEMIs receiving Medicaid or private 
insurance, respectively,(61)  in unadjusted analyses, Medicaid 
beneficiaries had lower rates of coronary revascularisation and 
higher rates of in-hospital mortality compared with privately 
insured individuals. Similar results were found in propensity-
matched cohorts. Further studies are needed to identify and 
understand the causes of the variation in STEMI outcomes by 
insurance status.
Black vs. White patients
In a US cohort of 6 402 patients, self-identified black and 
white patients differed in several clinical and socioeconomic 
characteristics.(62) The higher the prevalence of characteristics 
associated with being black, the higher the 5-year mortality 
rate, but no differences were observed between black and 
white patients with similar characteristics. Thus, a greater pre-
valence of characteristics associated with black race, but not 
race itself, was associated with higher mortality risk after AMI.
CONCLUSIONS
Important data from large randomised trials have augmented 
the management of patients presenting with ACS. Importantly, 
recognition of the clinical spectrum of ACS has expanded in 
recent years and atypical forms, besides the classical STEMI 
and NSTEMI, such as takotsubo syndrome, coronary dissec-
tion, MINOCA, and myocarditis, have been increasingly 
recognised, characterised and their causes and mechanisms 
defined (Figure 6). The management of these novel forms 
of ACS is still not evidence-based, but significant progress 
has been made recently. Furthermore, disparities in the 
implementation of guideline-based therapies are increasingly 
addressed to the benefit of the patient population at large.
The opinions expressed in this article are not necessarily 
those of the Editors of the European Heart Journal or of the 
European Society of Cardiology.
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15. Marinković G, Grauen Larsen H, Yndigegn T, et al. Inhibition of pro-
inflammatory myeloid cell responses by short-term S100A9 blockade 
improves cardiac function after myocardial infarction. Eur Heart J 2019;
40:2713-2723.
16. Tang TWH, Chen HC, Chen CY, et al. Loss of gut microbiota alters immune 
system composition and cripples postinfarction cardiac repair. Circulation 
2019;139:647-659.
17. Scally C, Abbas H, Ahearn T, et al. Myocardial and systemic inflammation 
in acute stress-induced (takotsubo) cardiomyopathy. Circulation 2019;
139:1581-1592.
18. Templin C, Hanggi J, Klein C, et al. Altered limbic and autonomic pro-
cessing supports brain-heart axis in takotsubo syndrome. Eur Heart J 
2019;40:1183-1187.
19. Boeddinghaus J, Nestelberger T, Twerenbold R, et al.; APACE, BACC, and 
TRAPID-AMI Investigators. Impact of age on the performance of the ESC 
0/1h-algorithms for early diagnosis of myocardial infarction. Eur Heart J 
2018;39:3780-3794.
20. Twerenbold R, Costabel JP, Nestelberger T, et al. Outcome of applying the 
ESC 0/1-hour algorithm in patients with suspected myocardial infarction. 
J Am Coll Cardiol 2019;74:483-494.
21. Januzzi JLJr, Mahler SA, Christenson RH, et al. Recommendations for 
institutions transitioning to high-sensitivity troponin testing: JACC Scientific 
Expert Panel. J Am Coll Cardiol 2019;73:1059-1077.
22. Gibson CM, Holmes D, Mikdadi G, et al. Implantable cardiac alert system 
for early recognition of ST-segment elevation myocardial infarction. J Am 
Coll Cardiol 2019;73:1919-1927.
23. Mani P, Puri R, Schwartz GG, et al. Association of initial and serial C-reactive 
protein levels with adverse cardiovascular events and death after acute 
coronary syndrome: A secondary analysis of the VISTA-16 trial. JAMA 
Cardiol 2019;4:314-320.
24. Asleh R, Enriquez-Sarano M, Jaffe AS, et al. Galectin-3 levels and outcomes 
after myocardial infarction: A population-based study. J Am Coll Cardiol 
2019;73:2286-2295.
25. Farag M, Spinthakis N, Gue YX, et al. Impaired endogenous fibrinolysis in 
ST-segment elevation myocardial infarction patients undergoing primary 
percutaneous coronary intervention is a predictor of recurrent cardiovas-
cular events: The RISK PPCI study. Eur Heart J 2019;40:295-305.
26. Li XS, Obeid S, Wang Z, et al. Trimethyllysine, a trimethylamine N-oxide 
precursor, provides near- and long-term prognostic value in patients 
presenting with acute coronary syndromes. Eur Heart J 2019;40:2700-2709.
27. Guerin M, Silvain J, Gall J, et al. Association of serum cholesterol efflux 
capacity with mortality in patients with ST-segment elevation myocardial 
infarction. J Am Coll Cardiol 2018;72:3259-3269.
28. Lindholm D, James SK, Gabrysch K, et al. Association of multiple biomarkers 
with risk of all-cause and cause-specific mortality after acute coronary 
syndromes: A secondary analysis of the PLATO biomarker study. JAMA 
Cardiol 2018;3:1160-1166.
29. Androulakis AFA, Zeppenfeld K, Paiman EHM, et al. Entropy as a novel 
measure of myocardial tissue heterogeneity for prediction of ventricular 
arrhythmias and mortality in post-infarct patients. JACC Clin Electrophysiol 
2019;5:480-489.
30. Schupke S, Neumann FJ, Menichelli M, et al.; ISAR-REACT 5 Trial 
Investigators. Ticagrelor or prasugrel in patients with acute coronary syn-
dromes. N Engl J Med 2019;381:1524-1534.
31. Redfors B, Dworeck C, Haraldsson I, et al. Pretreatment with P2Y12 
receptor antagonists in ST-elevation myocardial infarction: a report from 
the Swedish Coronary Angiography and Angioplasty Registry. Eur Heart J 
2019;40:1202-1210.
32. Ibanez B, James S, Agewall S, et al.; ESC Scientific Document Group. 2017 
ESC Guidelines for the management of acute myocardial infarction in 
patients presenting with ST-segment elevation: The Task Force for the 
management of acute myocardial infarction in patients presenting with ST-
segment elevation of the European Society of Cardiology (ESC). Eur Heart J 
2018;39:119-177.
33. Abtan J, Steg PG. Pre-treatment with a P2Y12 antagonist before PCI in 
STEMI: Why should we wait? Eur Heart J 2019;40:1211-1213.
34. Lemkes JS, Janssens GN, van der Hoeven NW, et al. Timing of revas-
cularisation in patients with transient ST-segment elevation myocardial 
infarction: A randomised clinical trial. Eur Heart J 2019;40:283-291.
35. Mehta SR, Wood DA, Storey RF, et al.; COMPLETE Trial Steering Committee 
and Investigators. Complete revascularisation with multivessel PCI for 
myocardial infarction. N Engl J Med 2019;381:1411-1421.
36. Stone GW, Genereux P, Harrington RA, et al. Impact of lesion complexity 
on peri-procedural adverse events and the benefit of potent intravenous 
platelet adenosine diphosphate receptor inhibition after percutaneous 
coronary intervention: Core laboratory analysis from 10 854 patients from 
the CHAMPION PHOENIX trial. Eur Heart J 2018;39:4112-4121.
156
REFERENCES
37. Fujino A, Kadohira T, Redfors B, et al. Significant association among residual 
SYNTAX score, non-culprit major adverse cardiac events, and greyscale and 
virtual histology intravascular ultrasound findings: A substudy from the 
PROSPECT study. EuroIntervention 2019;14:1676-1684.
38. Johnson TW, Raber L, di Mario C, et al. Clinical use of intracoronary imaging. 
Part 2: Acute coronary syndromes, ambiguous coronary angiography 
findings, and guiding interventional decision-making: an expert consensus 
document of the European Association of Percutaneous Cardiovascular 
Interventions. Eur Heart J 2019;40:2566-2584.
39. Aradi D, Gross L, Trenk D, et al. Platelet reactivity and clinical outcomes in 
acute coronary syndrome patients treated with prasugrel and clopidogrel: 
Apre-specified exploratory analysis from the TROPICAL-ACS trial. Eur 
Heart J 2019;40:1942-1951.
40. De Maria GL, Alkhalil M, Wolfrum M, et al. Index of microcirculatory 
resistance as a tool to characterise microvascular obstruction and to predict 
infarct size regression in patients with STEMI undergoing primary PCI. JACC 
Cardiovasc Imaging 2019;12:837-848.
41. Nepper-Christensen L, Lønborg J, Høfsten DE, et al. Impact of diagnostic 
ECG-to-wire delay in STEMI patients treated with primary PCI: A DANAMI-3 
substudy. EuroIntervention 2018;14:700-707.
42. De Maria GL, Cuculi F, Patel N, et al. How does coronary stent implantation 
impact on the status of the microcirculation during primary percutaneous 
coronary intervention in patients with ST-elevation myocardial infarction? 
Eur Heart J 2015;36:3165-3177.
43. Morales-Ponce FJ, Lozano-Cid FJ, Martinez-Romero P, et al. Intracoronary 
tenecteplase versus abciximab as adjunctive treatment during primary 
percutaneous coronary intervention in patients with anterior myocardial 
infarction. EuroIntervention 2019;14:1668-1675.
44. McCartney PJ, Eteiba H, Maznyczka AM, et al.; T-TIME Group. Effect of low-
dose intracoronary alteplase during primary percutaneous coronary 
intervention on microvascular obstruction in patients with acute myocardial 
infarction: A randomised clinical trial. JAMA 2019;321:56-68.
45. Mathias WJr, Tsutsui JM, Tavares BG, et al.; MRUSMI Investigators. 
Sonothrombolysis in ST-segment elevation myocardial infarction treated 
with primary percutaneous coronary intervention. J Am Coll Cardiol 
2019;73:2832-2842.
46. Hausenloy DJ, Kharbanda RK, Moller UK, et al.; CONDI-2/ERIC-PPCI 
Investigators. Effect of remote ischaemic conditioning on clinical outcomes in 
patients with acute myocardial infarction (CONDI-2/ERIC-PPCI): A single-
blind randomised controlled trial. Lancet 2019;394:1415-1424.
47. Hall M, Bebb OJ, Dondo TB, e al. Guideline-indicated treatments and 
diagnostics, GRACE risk score, and survival for non-ST elevation myocardial 
infarction. Eur Heart J 2018;39:3798-3806.
48. Szummer K, Wallentin L, Lindhagen L, et al. Relations between implementa-
tion of new treatments and improved outcomes in patients with non-ST-
elevation myocardial infarction during the last 20 years: Experiences from 
SWEDEHEART registry 1995 to 2014. Eur Heart J 2018;39:3766-3776.
49. Doimo S, Fabris E, Piepoli M, et al. Impact of ambulatory cardiac rehabilitation 
on cardiovascular outcomes: A long-term follow-up study. Eur Heart J 
2019;40:678-685.
50. Jones DA, Rathod KS, Koganti S, et al. The association between the public 
reporting of individual operator outcomes with patient profiles, procedural 
management, and mortality after percutaneous coronary intervention: An 
observational study from the Pan-London PCI (BCIS) Registry using an 
interrupted time series analysis. Eur Heart J 2019;40:2620-2629.
51. Berg DD, Wiviott SD, Braunwald E, et al. Modes and timing of death in 
66 252 patients with non-ST-segment elevation acute coronary syndromes 
enrolled in 14 TIMI trials. Eur Heart J 2018;39:3810-3820.
52. Bradley SM, Borgerding JA, Wood GB, et al. Incidence, risk factors, and 
outcomes associated with in-hospital acute myocardial infarction. JAMA 
Netw Open 2019;2:e187348.
53. Saw J, Starovoytov A, Humphries K, et al. Canadian spontaneous coronary 
artery dissection cohort study: In-hospital and 30-day outcomes. Eur Heart J 
2019;40:1188-1197.
54. Gili S, Cammann VL, Schlossbauer SA, et al. Cardiac arrest in takotsubo 
syndrome: results from the InterTAK Registry. EurHeart J 2019;40:
2142-2151.
55. Cammann VL, Sarcon A, Ding KJ, et al. Clinical features and outcomes of 
patients with malignancy and takotsubo syndrome: Observations from the 
International Takotsubo Registry. J Am Heart Assoc 2019;8:e010881.
56. Dreyer RP, Tavella R, Curtis JP, et al. Myocardial infarction with non-
obstructive coronary arteries as compared with myocardial infarction and 
obstructive coronary disease: Outcomes in a Medicare population. Eur Heart 
J 2019; doi:10.1093/eurheartj/ehz403.
57. Stehli J, Martin C, Brennan A, et al. Sex differences persist in time to pre-
sentation, revascularisation, and mortality in myocardial infarction treated 
with percutaneous coronary intervention. J Am Heart Assoc 2019;8:e012161.
58. Meyer MR, Bernheim AM, Kurz DJ, et al. Gender differences in patient and 
system delay for primary percutaneous coronary intervention: Current 
trends in a Swiss ST-segment elevation myocardial infarction population. 
Eur Heart J Acute Cardiovasc Care 2019;8:283-290.
59. Hao Y, Liu J, Liu J, et al. Sex differences in in-hospital management and 
outcomes of patients with acute coronary syndrome. Circulation 2019;
139:1776-1785.
60. Vicent L, Ariza-Solé A, Alegre O, et al. Octogenarian women with acute 
coronary syndrome present frailty and readmissions more frequently than 
men. Eur Heart J Acute Cardiovasc Care 2019;8:252-263.
61. Patel N, Gupta A, Doshi R, et al. In-hospital management and outcomes 
after ST-segment-elevation myocardial infarction in Medicaid beneficiaries 
compared with privately insured individuals. Circ Cardiovasc Qual Outcomes 
2019;12:e004971.
62. Graham GN, Jones PG, Chan PS, et al. Racial disparities in patient 
characteristics and survival after acute myocardial infarction. JAMA Netw 
Open 2018;1:e184240.
ACUTE CORONARY SYNDROMES
